Bayer aims to be in the top five pharmaceutical companies in Asia Pacific's Emerging markets

In the first quarter of 2011, global sales of Bayer HealthCare Pharmaceuticals rose by 4.7 percent to EUR 2,649 million. Bayer's pharmaceutical division already generates more than 20 percent of its annual sales in the Emerging Markets. Based on continued good results over the past years, Bayer HealthCare Pharmaceuticals aims to be among the top five pharmaceutical companies in the Emerging Markets by 2015 and to scale up the share of sales from these markets to one third.

Geographic expansion, innovative products such as Xarelto®, and promising candidates such as VEGF Trap-Eye, Alpharadin and others from a well-filled pipeline, as well as increased R&D activities in the Emerging Markets, are expected to become the core elements to drive future growth. "We want to further expand our already strong footprint in the Emerging Markets, where our company has already established a long tradition," said Bayer HealthCare Pharmaceuticals' President Andreas Fibig in Singapore. "The so called "pharmerging markets' are predicted to grow at a rate of 15-17 % in 2011 alone. They therefore play a key role in our growth strategy. We believe we are well positioned for success because of our ability to adapt to local markets and the specific needs of patients there, our excellent local execution capabilities and our strong research ability."